

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock code: 1093)

**APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR
AND
COMPLIANCE WITH RULE 3.10A OF THE LISTING RULES**

The board of directors (the **Board**) of CSPC Pharmaceutical Group Limited (the **Company**) hereby announces that Mr. Chen Chuan (**Mr. CHEN**) was appointed as an Independent Non-Executive Director of the Company with effect from 6 June 2016.

Mr. CHEN, aged 52, currently serves as the Medical Advisor of Beijing Health Vision Medical Technology Information Co., Ltd. From 2006 to 2012, Mr. CHEN was a Vice President of Johnson & Johnson China responsible for government affairs. From 1999 to 2006, Mr. CHEN was the Diabetes Business Unit Head and Government Affairs Director of Eli Lilly China. Mr. CHEN is also a director of Beijing Dong Fang Ming Kang Medical Equipment Co., Ltd. (quoted on the National Equities Exchange and Quotations System) and an independent director of Jiangsu Wuzhong Industrial Co., Ltd. (listed on Shanghai Stock Exchange). Mr. CHEN holds a Bachelor's degree in Medicine from Norman Bethune University of Medical Science and a Master's degree in Science from Albert Einstein College of Medicine at Yeshiva University.

Mr. CHEN has entered into a service contract with the Company for a term of three years commencing from 6 June 2016. His appointment is subject to retirement by rotation at annual general meeting of the Company in accordance with the articles of association of the Company. Mr. CHEN will be entitled to receive an annual director's fee of HK\$100,000. His emoluments are determined having giving consideration to the prevailing market practice, the Company's remuneration policy and the level of responsibility.

Saved as disclosed above, Mr. CHEN did not hold any directorship in any listed company in the last three years. Mr. CHEN does not have any relationship with any directors, senior management or substantial shareholders of the Company and does not hold other positions with the Company or other members of the Company. As at the date of this announcement, Mr. CHEN does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, there are no other matters concerning the appointment of Mr. CHEN that need to be brought to the attention of the shareholders of the Company nor any information required to be disclosed under Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the **Listing Rules**).

Following Mr. CHEN's appointment, the Board comprises fifteen members with nine executive directors, one non-executive director and five independent non-executive directors and accordingly, the Company will be in compliance with the requirement under Rule 3.10A of the Listing Rules for having independent non-executive directors representing at least one-third of the Board.

The Company extends its warmest welcome to Mr. CHEN to join the Board.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 6 June 2016

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. CHAK Kin Man, Mr. PAN Weidong, Mr. WANG Shunlong, Mr. WANG Huaiyu, Mr. LU Jianmin, Mr. WANG Zhenguo, Mr. WANG Jinxu, and Mr. LU Hua as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.